Tilray Brands (NASDAQ:TLRY) could surge if the U.S. moves to reschedule marijuana from a Schedule I to a less restrictive category, a shift that would cut taxes and ease research for operators.
Key Points
Rescheduling lowers federal tax burdens for U.S. cannabis firms by removing Section 280E penalties, and it creates a clearer path for scientific study. The Canadian producer Tilray, however, will not reap those tax savings because it operates north of the border. Investors view the move as the first major step toward full legalization, though the timeline remains uncertain.
Rescheduling primarily helps U.S. cannabis operators
The federal government this year announced a proposal to reclassify medical marijuana products from Schedule I to Schedule III, a change that would permit broader research and reduce the crushing tax load of Section 280E. Companies already active in the United States stand to benefit most, as lower taxes could improve profitability and attract further investment.
Investors should be careful not to overreact to any rescheduling news
While the prospect of rescheduling lifts sentiment, legalization is not guaranteed and could take years to materialize. Tilray’s share price has plunged 76% over the past year, illustrating how quickly optimism can evaporate when reality sets in. The stock may rally temporarily on reform headlines, only to surrender gains as the process drags on.
Should you buy stock in Tilray Brands right now?
The Motley Fool’s stock‑advisor team recently ranked the top 10 investment picks, and Tilray was absent from the list. Past recommendations such as Netflix in 2004 and Nvidia in 2005 delivered returns exceeding 300,000% and 1.1 million%, respectively, illustrating the potential of well‑chosen stocks. The advisor’s average return stands at 852%, far outpacing the S&P 500’s 203%.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands and maintains a full disclosure policy.
